Cellular Immunotherapy Market Report 2026

Cellular Immunotherapy Market Overview

• Cellular Immunotherapy market size has reached to $6.56 billion in 2025 • Expected to grow to $12.5 billion in 2030 at a compound annual growth rate (CAGR) of 13.7% • Growth Driver: Role Of Cellular Immunotherapies In Addressing Rising Prevalence • Market Trend: Major Companies Drive Innovation in Cellular Immunotherapy for Enhanced Treatment Efficacy • North America was the largest region in 2025.

What Is Covered Under Cellular Immunotherapy Market?

Cellular immunotherapy refers to a sort of immunotherapy in which a patient receives T cells, an immune cell, to aid the body in fighting diseases like cancer. It is a cutting-edge kind of treatment that uses the body's immune system to combat cancer. The main therapies of cellular immunotherapy are tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy that involves extracting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro, and then infusing them back into patients to treat them. The various primary indications include b-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin lymphoma, and others, and are used for the treatment of prostate cancer, breast cancer, skin cancer, ovarian cancer, brain tumors, lung cancer, and others.

What Is The Cellular Immunotherapy Market Growth Forecast?

The cellular immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $12.5 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to expansion into solid tumors, innovation in nk cell therapy, scalable manufacturing technologies, supportive regulatory frameworks, increased oncology investment. Major trends in the forecast period include rapid growth of car-t cell therapies, expansion of allogeneic cell therapies, increasing use in hematologic malignancies, advancements in t cell engineering, rising clinical trial activity.

Global Cellular Immunotherapy Market Segmentation

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy 2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications 3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications Subsegments: 1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy 2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy 3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies 4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications

What Is The Driver Of The Cellular Immunotherapy Market?

The rising prevalence of cancer is expected to propel the growth of the cellular immunotherapy market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rising prevalence of cancer is largely due to an aging population, lifestyle factors, and improved screening and diagnosis. Environmental exposures and genetic predispositions also play significant roles in increasing incidence rates. Cellular immunotherapy boosts the immune response against cancer by specifically targeting tumor cells, improving survival rates. This approach, combined with other treatments, may lead to a decrease in cancer incidence and recurrence. For instance, in March 2024, according to MAC Clinical Research, a UK-based cancer research organization, the estimated number of people living with cancer in the United Kingdom is expected to increase from about 3 million currently to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the rising prevalence of cancer is driving the growth of the cellular immunotherapy industry.

Key Players In The Global Cellular Immunotherapy Market

Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

Global Cellular Immunotherapy Market Trends and Insights

Major companies operating in the cellular immunotherapy market are focused on developing technological advancements such as immunotherapy. To enhance treatment efficacy and expand applications. Their focus includes personalized medicine, combination therapies, and scalable manufacturing to improve patient outcomes. Immunotherapy is a treatment that harnesses the body’s immune system to fight diseases, especially cancer. It can involve boosting immune responses or providing targeted therapies to enhance immune activity against specific cells. For instance, in December 2023, Max Healthcare Institute Limited is an India-based healthcare service provider company. CAR-T cell therapy is a revolutionary cancer treatment that utilizes genetically engineered T cells to specifically target and destroy cancer cells, offering a personalized approach. It provides durable remission rates, particularly for resistant blood cancers, while minimizing damage to healthy tissues.

What Are Latest Mergers And Acquisitions In The Cellular Immunotherapy Market?

In January 2023, AstraZeneca., a UK-based pharmaceutical industry company, acquired Neogene Therapeutics for an undisclosed amount. With this acquisition, AstraZeneca aims to enhance its oncology portfolio and accelerate the development of innovative T-cell receptor therapies for solid tumours through its acquisition of Neogene Therapeutics. Neogene Therapeutics, Inc., a US-based biotechnology company. It specializes in personalized cellular immunotherapy, designing T-cells to specifically target cancer cells.

Regional Insights

North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cellular Immunotherapy Market?

The cellular immunotherapy market includes revenues earned by entities by inventing, developing, administering, and understanding engineered immune effector cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cellular Immunotherapy Market Report 2026?

The cellular immunotherapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cellular immunotherapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.